Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immune Dysregulation Disorder Clear all
Withdrawn Not applicable Interventional

Response of Urticaria to Stress Intervention

NCT01047137
View directory record Official record
Conditions
Chronic Urticaria
Interventions
Psychological Stress Intervention, General Supportive Therapy
Behavioral
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Jun 10, 2026, 10:51 AM EDT
Active, not recruiting Phase 2 Interventional

Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies

NCT02990819
View directory record Official record
Conditions
Immunodeficiencies, Immune Dysregulation Syndromes
Interventions
Apha/beta T and CD19+ cell depletion using CliniMACS device
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 10, 2026, 10:51 AM EDT
Recruiting No phase listed Observational

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

NCT06339177
View directory record Official record
Conditions
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jun 10, 2026, 10:51 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without Thymectomy

NCT07416201
View directory record Official record
Conditions
Down Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 120 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2040
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 10, 2026, 10:51 AM EDT
Completed Not applicable Interventional

Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients

NCT04818970
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Autoimmune Diseases, Coagulation Disorder, Blood
Interventions
Narrow Band ultraviolet B-Band Light, non Narrow Band ultraviolet B-Band Light
Device
Lead sponsor
Cytokind, Inc.
Industry
Eligibility
50 Years to 110 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Jun 10, 2026, 10:51 AM EDT
Not listed Phase 2Phase 3 Interventional

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

NCT02155803
View directory record Official record
Conditions
Sarcoidosis, Hypercalcemia Due to Sarcoidosis
Interventions
ACTHAR Gel (adrenocorticotropic hormone)
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Jun 10, 2026, 10:51 AM EDT
Recruiting Phase 1 Interventional

CD4^LVFOXP3 in Participants With IPEX

NCT05241444
View directory record Official record
Conditions
IPEX
Interventions
CD4^LVFOXP3
Biological
Lead sponsor
Bacchetta, Rosa, MD
Other
Eligibility
4 Months to 35 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jun 10, 2026, 10:51 AM EDT
Completed No phase listed Observational

The Effects of a Clean Room Sleeping Environment on Elemental and Chemical Concentrations in Children With Autism

NCT02195401
View directory record Official record
Conditions
Autism
Interventions
Cleanroom
Other
Lead sponsor
The Children's Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Jun 10, 2026, 10:51 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

NCT05595369
View directory record Official record
Conditions
Long COVID, Long Covid19
Interventions
Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control
Drug
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jun 10, 2026, 10:51 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

NCT03663933
View directory record Official record
Conditions
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders, Immune System Diseases, Common Variable Immunodeficiency
Interventions
e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning, GVHD Prophylaxis, Allogeneic HSC, Bisulfan, Prednisone, Cyclophosphamide, MMF, Mesna, Tacrolimus, Pentostatin, PFTs, DEXA, Bone Marrow Aspirate & Biopsy, EKG, 2D ECHO
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2030
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jun 10, 2026, 10:51 AM EDT
Recruiting Phase 2 Interventional

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

NCT07284641
View directory record Official record
Conditions
Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome, STAT 1 Gain of Function, STAT 3 Gain of Function, Hypomorphic RAG1 Deficiency, CD40 Ligand Deficiency, Mendelian Susceptibility to Mycobacterial Disease, GATA2 Associated Immunodeficiency, CD40 Deficiency, Hypomorphic RAG2 Deficiency, Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome, Omenn Syndrome, Chronic Granulomatous Disease
Interventions
Hematopoietic stem cell transplant (HSCT)
Biological
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 10, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Analysis of Post-exertional Malaise Using a Two-day CPET in People With ME/CFS

NCT04026425
View directory record Official record
Conditions
Myalgic Encephalomyelitis, Chronic Fatigue Syndrome
Interventions
Two-day cardiopulmonary exercise test
Other
Lead sponsor
Ithaca College
Other
Eligibility
18 Years to 70 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Torrance, California • Ithaca, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Jun 10, 2026, 10:51 AM EDT
Active, not recruiting Phase 2 Interventional

Leniolisib for Immune Dysregulation in PIDs

NCT06549114
View directory record Official record
Conditions
Primary Immunodeficiency Disorders (PIDs)
Interventions
Leniolisib
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 10, 2026, 10:51 AM EDT
Recruiting Not applicable Interventional

Obesity, Metabolic Dysregulation and the Airway Epithelium in Asthmatics

NCT03215836
View directory record Official record
Conditions
Asthma, Obesity, Metabolic Syndrome
Interventions
Bronchoscopy and Nasal Epithelium Brush Sampling
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Jun 10, 2026, 10:51 AM EDT
Recruiting Phase 2 Interventional

Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation

NCT06990529
View directory record Official record
Conditions
PIDs Linked to PI3K
Interventions
Leniolisib
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Bethesda, Maryland • Burlington, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 10, 2026, 10:51 AM EDT